AI and ML Enhance ECG Interpretation

By Michael Awood

September 22, 2023

We’ve shown how AI and ML help diagnose and manage heart problems. New research has recently shown that a new ML model can improve ECG data interpretation, reducing misdiagnosis and optimizing patient monitoring data.

A further step is to look at monitoring and early disease detection while patients are being monitored within the home space. This is something our recent insight article has touched on.

By using traditional signal processing and ML, this model can overcome challenges caused by noisy data. They evaluated it using real-world single-lead ECG data from acutely ill patients receiving care at home as part of a ‘home hospital’ program. The model showed excellent performance, with a sensitivity of 98%, a specificity of 100%, an accuracy of 98%, a positive predictive value of 100%, and a negative predictive value of 93%.

It was effective in interpreting telemetry feeds for acutely ill patients. The current systems can detect atrial fibrillation with 92% accuracy and paroxysmal supraventricular tachycardia with 93% accuracy. However, the new ML algorithm could enhance arrhythmia identification.

The ML model can monitor chronically ill patients during medication changes or diagnose hidden arrhythmia. It could form the basis of a system that consistently monitors cardiac health through arrhythmia detection.

The study evaluated a single-lead ECG hybrid ML algorithm using data from acutely ill patients within a ‘home hospital’ programme. It shows the potential of AI and ML to enhance healthcare delivery and patient outcomes, particularly in cardiology. Investigating the impact of long-term arrhythmia burden on health outcomes is crucial for future research.

Reference url

Recent Posts

NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable Healthcare
Sandoz's Strategic Momentum in Biosimilars and Generics Sandoz's biosimilars strategy, as highlighted during the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlines its prog...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Trump's Davos 2026 Economic Revival: Claimed Policy Impacts and Metrics In his special address at the World Economic Forum's Annual Meeting 2026 in Davos, Switzerland, U.S. President Donald J. Trump highlighted t...